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This is a continuation of our eﬀorts to maintain a record of the evolution of HIV-1 infection in Puerto Rico by monitoring
the expression levels of antiretroviral drug-resistance-associated mutations. Samples from 2,500 patients from 2006–2010 were
analyzed using the TruGene HIV-1 genotyping kit and the OpenGene DNA sequencing system. Results show that 58.8% of males
and65.3%offemaleshadHIV-1withresistancetoatleastonemedication.TheaveragenumberofHIVmutationswas6.0inmales
and 6.1 in females. Statistically signiﬁcant diﬀerences between men and women were recorded in the levels of HIV-1 expressed
mutations and antiretroviral drug resistance. The most prevalent antiretroviral medication resistance shifted from zalcitabine to
nevirapine and efavirenz in the ﬁve-year period. M184V and L63P were the dominant mutations for the reverse transcriptase and
the protease genes, respectively, but an increase in the incidence of minority mutations was observed.
1.Introduction
Puerto Rico has one of the highest incidences of HIV
infections among the United States and it’s jurisdictions.
The oﬃcial data collected by the Puerto Rico Department
of Health indicate that the number of persons living with
HIV increased from 39,455 to 43,400 from 2006 to 2010 and
that 5,027 new diagnoses were performed during the same
period of time (1,460 in 2006, 1,016 in 2007, 975 in 2008,
844 in 2009, and 732 in 2010) [1]. A comprehensive analysis
of the HIV population in Puerto Rico was performed by
the US Centers for Disease Control and Prevention (CDC)
using the data for 2006. In that particular year, 71% of
the new diagnosed individuals were males. By age group,
the greatest number of diagnoses of HIV infection occurred
among those aged 30 to 39 years, followed by those aged
40 to 49 years. Among males, the most common mode of
HIV transmission was injection-drug use (40%), followed
by male-to-male sexual contact (30%). Among females, the
most common mode of HIV transmission was high-risk
heterosexual contact (73%), followed by injection-drug use
(27%). The rate of diagnosis of HIV infection in Puerto
Rico in 2006 was 45.0 per 100,000 population, twice the
estimated US rate (22.8) and 1.5 times the estimated rate
for Hispanics in the United States (29.4). The incidence rate
among males in Puerto Rico (62.0) was 1.8 times the rate
among US males (34.3) and 1.4 times the rate among US
Hispanic males (43.1). The incidence rate among females in
Puerto Rico (29.8) was 2.5 times the rate among US females
(11.9) and 2.0 times the rate in US Hispanic females (14.4)
[2, 3]. However, comparisons between the rates for Puerto
Rico and the rates for Hispanics in the United States should
consider diﬀerences in the two populations since Hispanics
intheUnitedStatesincludepeopleofdiversenationalorigins
whose behavioral characteristics might diﬀer from Hispanics
in Puerto Rico [4]. One major diﬀerence between the HIV2 AIDS Research and Treatment
epidemiology in Puerto Rico and the United States is that
injection-drug use continues to be the most common mode
of HIV transmission in Puerto Rico, whereas most new HIV
infections in the United States are attributed to male-to-
male sexual contact [5, 6]. This observation is in agreement
with previous reports that highlight a greater prevalence of
injection-drug use and high-risk health behaviors related to
injection-drug use (e.g., frequency of injecting and sharing
syringes and other drug paraphernalia) in Puerto Rico than
in the United States [4, 7].
Further analysis of the 2008 US HIV surveillance data
generated an estimated lifetime risk for HIV diagnosis for
the residents of Puerto Rico at 2.1%. This is approxi-
mately 3.5 times greater than that for whites and, among
racial/ethnic populations, was greater than all populations
except Blacks/African Americans [8]. The aforementioned
data reﬂect the disparate nature of the HIV epidemic among
Latinos in general and Puerto Ricans in particular. The
national HIV/AIDS strategy calls for increased focus on
interventions for Hispanics/Latinos, such as culturally and
linguistically appropriate interventions that include eﬀective
communication strategies, expansion of HIV testing and
diagnosis, and improved access to prevention, care, and
treatment services to reduce the number of new HIV
infections. The goal is to lower the estimated life risk for HIV
diagnosis and to reduce the disproportionate impact of HIV
in the Hispanic/Latino population [9].
The introduction of highly active antiretroviral therapy
(HAART) into clinical practice for the treatment of HIV has
led to dramatic reductions in mortality and morbidity [10].
This is largely because antiretroviral combination therapy
can suppress the plasma HIV viral load below detectable
limits and cause gradual elevation in CD4 cell counts,
resulting in improved immune status for responsive patients
who are compliant with therapy [11]. The emergence of
drug-resistant viruses remains the limiting factor in HIV-1
management, being a major cause of treatment failure, AIDS
clinical progression, and death [12].
International guidelines focus on the importance of
tailoring antiretroviral therapy to the individual patient, on
the basis of HIV-1 genetic data, integrated with clinical,
laboratory, and therapeutic information [13, 14]. HIV drug-
resistance testing is an intricate part of the therapy cus-
tomization process to avoid the prescription of antiretroviral
drugsthatarenoteﬀectiveagainsttheviralvariantpresentin
the patient. Genetic testing relies on the sequencing of genes
essential for viral replication and survival, like the reverse
transcriptase (RT) and protease resistance (PR), to detect
mutations that are known to confer drug resistance.
Our institution has been providing HIV-genome
sequencing services in Puerto Rico since 2000. This study
is part of our continuing eﬀort to establish an HIV-1
resistance-monitoring system in Puerto Rico, and an
extension of previous reports that examined the prevalence
of HIV-1-resistant mutations in the island from 2000 to
2005 [15–17]. Signiﬁcant diﬀerences were recorded for
various viral mutations and drug resistance between men
and women from 2006 to 2010. Changes in drug resistance
trends are discussed.
2. Methods
2.1. Samples. The Immunoretrovirus Research Laboratory
located at the Universidad Central del Caribe in Bayam´ on,
Puerto Rico provided the HIV-1 genotyping results from
patients referred to the facility by their primary care
physicians. Whole blood from HIV-1-infected patients was
collected in tubes containing ethylenediaminetetra-acetic
acid (EDTA) as anticoagulant. Plasma was separated and
stored at −80◦C until RNA isolation. Samples were analyzed
from 2006 (245 women, 411 men, and 51 anonymous),
2007 (206 women, 384 men, and 18 anonymous), 2008 (245
women,445men,and16anonymous),2009(89women,224
men, and 27 anonymous) and 2010 (36 women, 54 men, and
49 anonymous).
Sex was the only demographic information disclosed by
most patients. No clinical data was available to describe
the relation between the genotyped samples and the newly
diagnosed individual or the proportion of drug-na¨ ıve to
drug-treated patients. A quality control system based on
unique patient identiﬁcation numbers was used to ensure
that duplicate samples were eliminated from the dataset. Our
samples represent approximately 6% of the HIV-infected
population in the island.
2.2. RNA Isolation. HIV-1 viral RNA was extracted using
the QIAGEN QIAamp Viral RNA Mini Kit (QIAGEN,
Valencia CA) as previously described [16]. Brieﬂy, 140µL
plasma was added to 560µLo fb u ﬀer AVL containing
carrier RNA in a microcentrifuge tube. Following incubation
at room temperature for 10min, 560µL of ethanol was
added and mixed. Two consecutive aliquots of 630µLw e r e
added to the QIAamp spin column and centrifuged at
8,000 revolutions/min−1 (rpm) for 1min. The QIAamp
spin column was transferred into a clean 2mL collection
tube followed by the addition of 500µLo fB u ﬀer AW1, a
centrifugation step as previously described, 500µLo fB u ﬀer
AW2, and another centrifuged at 14,000rpm for 3min.
The QIAamp spin column was placed in a clean 1.5mL
microcentrifuge and incubated with 60µLo fb u ﬀer AVE
at room temperature for 1min before the viral RNA was
harvested by a ﬁnal centrifugation step at 8,000rpm for
1min. The samples were stored at −80◦C until ready for
analysis.
2.3. Mutational Analysis and Drug Resistance Correlations.
Viral mutations were determined by analyzing the RNA
samples with the TruGene HIV-1 genotyping kit and the
OpenGene DNA sequencing system using a proprietary
interpretative algorithm developed by the manufacturer
(Siemens Healthcare Diagnostics, Deerﬁeld, IL).
2.4. Statistical Analysis. InStat 3 for Macintosh (GraphPad
Software Inc., La Jolla, CA) was used to perform the analysis.
Fisher’s exact test was performed. Statistical signiﬁcance was
set at P ≤ 0.05.AIDS Research and Treatment 3
3. Results
3.1. General Gender Distribution of Viral Mutations and
Resistance to Antiretrovirals. Of 2,500 patients studied over a
ﬁve-year period, the TruGene HIV-1 genotyping kit detected
viral strains harboring at least one mutation in 96.3% of
the women (791 of 821) and 96.9% of the men (1,471 of
1,518). Resistance to at least one medication was observed
in 65.3% of the women (536 of 821) and 58.8% of the men
(893 of 1,518). An average of 6.1 mutations was recorded per
women, while the corresponding result for men was slightly
less (6.0). Resistance to an average of 5.0 and 4.8 medications
was noted for females and males, respectively. Taking in
consideration only the patients infected with mutant viruses,
an average of 6.4 mutations per women and 6.2 mutations
per men was recorded. Likewise, the average number of
medication resistance events was 7.6 for the women and 8.1
for the men showing resistance to any medication.
3.2. Antiretroviral Drug Resistance as Determined by TruGene
HIV-1 Genotyping. Table 1 compares the levels of HIV-1
resistance to antiretroviral drugs from 2006 to 2010. In
2006, the highest rates of resistance were observed for
zalcitabine (ddC) (397 of 707, 56.2%), lamivudine (3TC)
(347 of 707, 49.1%), and atazanavir (ATV) (310 of 707,
43.8%). In 2007, the viral strains were most resistant to
emtricitabine (FTC) (272 of 608, 44.7%), ATV (218 of 608,
35.9%), and nelﬁnavir (NFV) (204 of 608, 33.6%), and
signiﬁcant diﬀerence between men and women was observed
for nevirapine (NVP) (P = 0.01) and efavirenz (EFV)
(P = 0.001). The same three antiretrovirals attained the
highest levels of resistance in the following two years with
themostresistanceeventsrecordedfor3TC/FTC(219of706,
31.0% for 2008 and 95 of 340, 27.9% for 2009), followed
by NVP (180 of 706, 25.5% in 2008 and 74 of 340, 21.8%
in 2009) and EFV (175 of 706, 24.8% in 2008 and 71 of
340, 20.9% in 2009). In the case of 2010, NVP and EFV
scored the highest level of resistance at 25 of 139 (18.0%)
each, followed by saquinavir/ritonavir (SQV/r) at 21 of 139
(15.1%). Signiﬁcant diﬀerence among genders was recorded
for 3TC/FTC (P = 0.03) for the last year of the study.
3.3. Reverse Transcriptase Resistance-Associated Mutations.
The ten most prevalent RT resistance-associated mutations
from 2006 to 2010 are reported in Table 2. M184V was the
dominant mutation for all the years included in this study
with frequencies of (322 of 707, 45.5%), (253 of 608, 41.6%),
(206 of 706, 29.2%), (88 of 340, 25.9%), and (14 of 139,
10.1%), respectively. M41L was the second most common
mutation for 2006 and the third most common mutation
for 2007, 2008, and 2010 with prevalences of (157 of 707,
22.2%), (106 of 608, 17.4%), (79 of 706, 11.2%), and (11 of
139, 7.9%) for these years. K103N was also among the most
important mutations since it was the third highest mutation
for 2006 and remained in second place for the duration of
the study with incidences of (152 of 707, 21.5%), (114 of
608, 18.8%), (143 of 706, 20.3%), (58 of 340, 17.1%), and
(12 of 139, 8.6%) during the ﬁve-year period. V118I was
the third highest mutation for 2009 with an occurrence of 38
of 340 (11.2%). Statistically signiﬁcant diﬀerences between
men and women were observed for K70R (P = 0.04) and
K219Q (P = 0.03) in 2006, K103N (P = 0.02) in 2007,
K219E (P = 0.03) in 2009 (data not shown), and V118I
(P = 0.03) in 2010.
3.4. Protease Resistance-Associated Mutations. As shown in
Table 3, the PR-associated mutations with the highest degree
of expression from 2006 to 2010 was L63P with frequencies
of (525 of 707, 74.3%), (429 of 608, 70.6%), (494 of 706,
70.0%), (238 of 340, 70.0%), and (93 of 139, 66.9%),
respectively. M36I was the second most common mutation
for 2006 (164 of 707, 23.2%), while this position was
occupied by V77I for the reminder of the study with
prevalences of (201 of 608, 33.1%), (222 of 706, 31.4%), (125
of 340, 36.8%), and (45 of 139, 32.4%). I13V was the third
highest mutation for 2006, 2007, and 2009 and was recorded
in (155 of 707, 21.9%), (190 of 608, 31.3%), and (109 of 340,
32.1%) of the specimens, respectively. Likewise, the third
place corresponded to I62V in 2008 (211 of 706, 29.9%) and
2010 (37 of 139, 26.6%). Statistically signiﬁcant diﬀerences
betweenmenandwomenwererecordedforA71V(P = 0.05)
andL90M(P = 0.04)in2006,andM36I(P = 0.005)in2008.
4. Discussion
This study is an eﬀort to establish an HIV-1 resistance-
monitoring system in Puerto Rico and a continuation of the
articles published in 2002, 2008, and 2010 that examined the
prevalence of HIV-1 mutations and antiretroviral resistance
in the island from 2000 to 2005 [15–17]. As highlighted
in our previous reports, statistically signiﬁcant diﬀerences
between genders were observed for both antiretroviral
resistance levels and mutation incidences. It is of interest
to note that some of the gender diﬀerences detected in
this study were also observed in previous years. In the case
of antiretroviral drug resistance, gender diﬀerences were
recorded for nevirapine in 2004 and 2007. The statistically
signiﬁcant results for the reverse transcriptase mutation
K70R have been noted for 2003 and 2006, while gender
diﬀerences for K103N were observed in 2005 and 2007.
Similarly, the protease resistance mutation L90M showed a
divergent result between men and women in 2003, 2005,
and 2006. Even though it is premature to draw conclusions
based on the recurrence of these events, gender diﬀerence
patterns may emerge once data from subsequent years are
made available for analysis.
The results also provide a glimpse on the evolving
nature of the HIV-1 viral strains circulating in Puerto
Rico. As illustrated in Table 1, resistance to zalcitabine and
lamivudinedominatedthedrugresistancelandscapein2006,
following the trend observed in the previous years [16, 17].
Resistance to emtricitabine/lamivudine and nevirapine was
more common in the intermediate years, followed by a
codominance of nevirapine and efavirenz in the last year
of the study. There is a dramatic diﬀerence in the range
of antiretroviral drug resistance observed from 2006 to4 AIDS Research and Treatment
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2010. In the ﬁrst year of the study, there was a diﬀerence
of approximately 56 percentual points between the most
abundant and the least common antiretroviral resistance
levels, and the gap closed in the subsequent years until a
diﬀerenceofonly15percentualpointswasobtainedfor2010.
The reverse transcriptase mutation results indicate that
M184V continues to be the most common mutation sur-
veyed in our studies. This is consistent with reports based on
large-scale HIV-1 genotypic analyses that identify M184V/I
as the most prevalent nucleoside and nucleotide-analog-RT-
inhibitor- (NRTI-) resistance mutations that overcome the
eﬀects of drugs like emtricitabine and lamivudine [18, 19].
M41L, the second most common mutation for 2006 and
the third most common mutation for 2007, 2008, and 2010,
is also a dominant NRTI-resistance mutation identiﬁed in
the same studies. K103N, the third most prevalent mutation
for 2006 and the second most common mutation from
2007 to 2010, is frequently observed among nonnucleoside-
RT-inhibitor-(NNRTI-) resistance mutations that neutralize
efavirenz and nevirapine [18, 20] and has been identiﬁed as
a prevalent mutation in other retrospective studies [21].
As in previous years, the most prevalent protease resis-
tance mutation corresponds to L63, a position that shows
a great variation of amino acid substitutions contributing
to antiretroviral drug resistance [22, 23]. M36I, a mutation
that allows faster in vitro HIV-1 replication regardless of
the presence of protease inhibitors, was the second most
common mutation for 2006 [24]. V77I, a variant that has
been identiﬁed as an important emerging substitution in
HIV epidemiology studies, was the second most common
mutation from 2007 to 2010 [25, 26]. The third position was
occupied by I13V in 2006, 2007, and 2009, while this place
corresponded to I62V in 2008 and 2010. These mutations
have been associated with poor virological response to
antiretroviral treatments [27–29].
The tables show a descending trend for most of the
mutations, accompanied by an increase in the incidence of
minority mutations. This observation is more evident in
Table 3 where mutations that did not appear on the top ten
mutations in previous years started to dominate the results
landscape by the end of the study period. For example, I15V,
a mutation highly prevalent in Chinese HIV-1+ patients who
are drug users [30], appeared for the ﬁrst time in 2007 with
a prevalence of 9.5% (data not shown), doubled in 2008, and
remained as one of the most common mutations for 2009
and 2010. This observation may be validated once the data
corresponding to the subsequent years are included in the
analysis. More information is needed before an ascending
tendency of minority mutations can be established with
certainty.
Although deaths of persons with HIV/AIDS reported
to the national HIV/AIDS surveillance system and US
Vital Statistics have followed similar patterns across most
demographic and behavioral strata, including gender, age,
geographic distribution, and race/ethnicity, substantial vari-
ation exists in the percentages of decline among diﬀerent
subgroups [31]. Members of minority racial/ethnic groups
have a higher propensity to discontinue antiretroviral (ARV)
therapy,experiencemorevirologicfailure,andshowelevated
morbidity [32–34]. In the particular case of Hispanics, this
ethnic group has been identiﬁed as one of the socioeconomic
disparities associated with suboptimal HIV care, including
delayed HIV diagnosis and treatment, early discontinuation
of therapy, higher ratios of progression of disease, and
death [35–38]. Gender disparities have also been observed
in the United States, and minority women are increasingly
disadvantaged [39, 40]. Poverty, low health literacy, lack of
family support, limited access to transportation, patient-
provider issues, the organizational infrastructure of the
health care facility visited, and the perceived HIV stigma
within their communities are some of the issues associated
with the inequality [41, 42]. The aforementioned problems,
along with the inclusion of gender-speciﬁc issues into
management strategies for HIV-infected women, including
preconception and reproductive counseling, should be taken
into consideration while developing health plans for these
patients [43, 44]. Research targeted towards the reduction
of HIV-related disparities, including the understanding of
HIV/AIDS prevalence in women and minority groups, the
detection of emerging incidence trajectories in these groups,
and obtaining more information on how HIV infection as a
chronic disease aﬀects these individuals and their commu-
nities remains a high priority for the National Institutes of
Health Trans-NIH AIDS research initiatives [45].
In the particular case of the race/ethnicity versus drug-
resistance correlation, studies reporting HIV drug-resistance
rates between races are contradictory since race is accounted
for diﬀerences in some publications [46], while others
noticed no diﬀerences attributable to race [47, 48]. In the
case of ARV therapy tolerance, race has been correlated with
alterationsinmetabolicandanthropometricmeasureswhere
Latinos experienced the most unfavorable changes [49].
Minorities are also at higher risks of experiencing speciﬁc
adverse events but not in the overall adverse event rates,
all-cause mortality, or rates of toxicity-related treatment
discontinuations [50]. A recent analysis of the data collected
in ten studies found that the risk for virologic failure among
patients with similar variant loads was higher among black
and Hispanic patients. This relationship persisted, even after
adjustment for diﬀerences in adherence rates, suggesting
that socioeconomic factors, diﬀerences in levels of drug or
alcoholabuse,orperhapsrace-speciﬁcpolymorphismsinthe
cytochrome P450 system may play an important role in this
diﬀerence [51].
Gender diﬀerences in ARV treatment outcomes and
drug-resistance mutations are also of interest. Several studies
from developed countries have not identiﬁed gender as a
predictor for primary drug resistance [52–54], while others
report that mutation prevalence is higher in males [46].
In a recent study, females showed 2-fold odds of having
virological failure compared with males at one year after
genotype resistance testing, independent of race or a history
of optimal treatment [55].
Treatments for HIV-infected women are usually based
on eﬃcacy and tolerability studies conducted in men since
women are typically underrepresented in ARV treatment
clinical trials [56, 57], and many female participants with-
draw their consent prior to the conclusion of the study8 AIDS Research and Treatment
[58, 59]. Similar pharmacokinetics, treatment responses,
and outcomes are recorded for men and women [60–
62], but females are more susceptible to ARV treatment
delay [63, 64], higher drug exposure due to lower weights
[65], and physiological and metabolic diﬀerences aﬀecting
drug absorbance, toxicity, and retention [57, 66]. Malaise
symptoms like rash, peripheral neuropathy, fatigue, weight
loss, and feelings of vertigo/dizziness are frequently reported
by women [67]. The aforementioned reasons, along with the
psychosocial factors aﬀecting treatment compliance [67, 68],
account for a higher rate of treatment changes and poor
adherence among women living with HIV.
Current evidence demonstrates that HIV ARV drug-
resistance in resource-limited sites has neither emerged nor
been transmitted to the degree that had initially been feared.
However, due to a lack of standardized methodologies,
HIV ARV resistance data from resource-limited sites can
be diﬃcult to interpret and may not provide the program-
matic evidence necessary for public health action [69]. As
predicted, the use of ARV drugs in resource-rich regions
has exerted an increased evolutionary pressure on the virus,
leading to a higher prevalence of antiretroviral drug resistant
variants even among treatment-na¨ ıve individuals. In the
particularcaseoftheUnitedStates,acohortstudyconducted
in New York city found that the prevalence of overall
transmitted resistance changed from 13.2% to 24.1% during
the periods of 1995 to 1998 and 2003 to 2004 [70], and
other studies reported an overall prevalence of transmitted
drug resistance between 5 and 20% [71, 72]. Even though no
speciﬁc drug resistance data has been published for Puerto
Rico, resistant rates may be similar between Puerto Rico and
the continental United States due to the observed shared
infection pattern maintained by the high level of travel
between the two jurisdictions.
Our study is limited by the lack of demographic and
behavioral data that would allow the performance of mul-
tivariate statistical analyses that could explain the driving
forcesbehindthereportedstatisticallysigniﬁcantdiﬀerences.
Likewise,clinicallyrelevantcomparisonsbetweendrug-na¨ ıve
and drug-experienced patients cannot be performed because
the patients included in the study did not disclose their
clinical history. TruGene was designed to detect HIV-1
subtype B, and even though some reports indicate that it
can perform well on diverse HIV-1 subtypes [73], we do not
know if the increase in prevalence of minority mutations
is aﬀected by the introduction on nonsubtype B variants
in the studied population. Furthermore, the assay detects
mutationsinthecodingregionsoftheRTandproteasegenes,
butitwasnotdesignedtoidentifymutationsinotherregions
of the viral genome that could contribute to ARV therapy
resistance.
According to the manufacturer, the rules for the TruGene
HIV-1 gentotyping assay are developed from the knowledge
of a world-renowned panel of HIV experts that meet
annually to review the latest HIV-1 clinical and research
data. The resistance eﬀects of mutations identiﬁed in the
HIV-1 sample by the OpenGene DNA sequencing system
are the culmination of a proprietary interpretative algorithm
that considers published and nonpublished data, the rec-
ommendations of the annual expert review panel as well as
alternative interpretative algorithms. Six TruGene guideline
rules were released during the study period (version 10 in
January of 2006, version 11 in September of 2006, version 12
inFebruaryof2007,version13inNovemberof2007,version
14 in February of 2009, and version 15 in December of 2009)
and present a major technical limitation. Since privacy issues
impede the electronic storage of patient data, previously
analyzed samples cannot be harmonized by being reanalyzed
using the latest software version that may detect formerly
unknown resistance patterns. Therefore, the periodic actu-
alization of the software to reﬂect the current state of
knowledgeofmutation-resistancecorrelationscanintroduce
artifacts that are beyond the control of the investigators.
For example, Table 1 shows a shift in antiretroviral drug
resistance from lamivudine in 2006 to emtricitabine in 2007
to lamivudine/emtricitabine for the rest of the study. Since
both drugs are associated with the same major mutations
[18], it is possible that the change in the mutation-resistance
correlationisdirectlyrelatedtosoftwareupdatesmadebythe
manufacturer. Therefore, it is recommended to emphasize
the results reported for the actual mutation rates because
the outcome will remain the same, even if the mutation’s
correlation to a speciﬁc drug changes in the future to
accommodate the evolving nature of our understanding of
the HIV antiretroviral drug resistance ﬁeld.
Like many commercial screening platforms, TruGene
is also aﬀected by its inability to detect the presence
of minority viral variants that can rapidly grow under
drug selection pressure and can contribute to treatment
failure [74–77]. This outcome may change once new high-
throughput sequencing methods with the ability to quantify
resistant variants, providing both proportional and absolute
numbers of sequencing reads with a mutation, are readily
available for clinical use. For example, ultradeep sequencing,
a promising emerging technology, has been used to interpret
ARV resistance in clinical trials [78, 79], and the ability of
clinical laboratories to perform the method was examined
in an international collaborative study [80]. On the other
hand, before these new sensitive resistance technologies can
be used to improve the clinical utility of viral genotyping
in a cost-eﬀective manner, important issues like a better
deﬁnition of the level of sensitivity required to detect drug-
resistant variants, the eﬀects diﬀerent variants have on
treatmentresponse,andtherequirementforgenotypicassays
to provide information on resistance mutation linkage must
be addressed by the scientiﬁc community [81, 82].
Aside from the aforementioned limitations, the fact
that gender diﬀerences in HIV mutations and ARV drug
resistance in Puerto Rican patients have been noted in the
past ten years could point out possible diﬀerences in ARV
treatment eﬃciency for this particular population. Our data
could be of value for prospective cohort studies designed
to study these diﬀerences in more detail, with the goal of
establishing HIV mutation and resistance models tailored
to the needs of Hispanics in general and Puerto Ricans in
particular.AIDS Research and Treatment 9
5. Conclusions
As observed in previous reports of HIV-1 mutation trends
and antiretroviral resistance for Puerto Rican patients, statis-
tically signiﬁcant diﬀerences between genders were observed
for both antiretroviral drug resistance levels and mutation
incidences in the reverse transcriptase and protease genes.
The most abundant antiretroviral drug resistance levels
shifted from zalcitabine to nevirapine and efavirenz, and
the gap between the most prevalent and the least common
antiretroviral drug resistance counts closed signiﬁcantly.
Even though M184V and L63P continue to be the most
prevalent mutations for the reverse transcriptase and the
protease genes, respectively, a descending trend was observed
for most of the mutations. An increase in the incidence
of minority mutations was detected, suggesting that less
common HIV-1 variants circulating in Puerto Rico may
grow rapidly in subsequent years. This observation may be
validated once the corresponding data are included in the
analysis. More information is needed before an ascending
tendency of minority mutations can be established with
certainty.
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